Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 2
1950 2
1951 5
1952 5
1953 6
1954 8
1956 7
1959 3
1960 2
1961 2
1962 2
1964 1
1967 1
1981 2
1982 3
1983 2
1984 3
1987 2
1991 1
1992 3
1993 2
1994 4
1996 9
1997 8
1998 6
1999 11
2000 7
2001 17
2002 16
2003 22
2004 24
2005 27
2006 28
2007 26
2008 24
2009 30
2010 29
2011 35
2012 28
2013 45
2014 25
2015 32
2016 34
2017 33
2018 31
2019 31
2020 22
2021 27
2022 30
2023 23
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

681 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for saccharated ferric oxide
Your search for saccharated ferricoxide retrieved no results
Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
Iwasaki T, Fujimori A, Nakanishi T, Okada S, Hanawa N, Hasuike Y, Kuragano T. Iwasaki T, et al. BMC Nephrol. 2021 Apr 8;22(1):124. doi: 10.1186/s12882-021-02320-2. BMC Nephrol. 2021. PMID: 33832448 Free PMC article.
METHODS: Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with saccharated ferric oxide (SFO) was administered at week 4. The changes in haematopoiesis-related biomarkers, including ERFE, i …
METHODS: Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with sacc …
Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.
Sato K, Shiraki M. Sato K, et al. Endocr J. 1998 Aug;45(4):431-9. doi: 10.1507/endocrj.45.431. Endocr J. 1998. PMID: 9881891 Free article. Review.
Saccharaed ferric oxide (SFO)-induced osteomalacia develops when excessive SFO infusions are administrated to patients with anemia for prolonged periods for a few years. ...
Saccharaed ferric oxide (SFO)-induced osteomalacia develops when excessive SFO infusions are administrated to patients with an …
Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M; Study Group. Kawabata H, et al. Int J Hematol. 2022 Nov;116(5):647-658. doi: 10.1007/s12185-022-03401-0. Epub 2022 Jul 6. Int J Hematol. 2022. PMID: 35790696 Free PMC article. Clinical Trial.
A multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisomaltose (FDI) versus saccharated ferric oxide (SFO) in Japanese patients with iron deficiency anemia associated with men …
A multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisom …
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees. Macdougall IC, et al. N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26. N Engl J Med. 2019. PMID: 30365356 Free article. Clinical Trial.
Iron Deficiency in Heart Failure: An Overview.
von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. von Haehling S, et al. JACC Heart Fail. 2019 Jan;7(1):36-46. doi: 10.1016/j.jchf.2018.07.015. Epub 2018 Dec 12. JACC Heart Fail. 2019. PMID: 30553903 Free article. Review.
Oral iron products have been shown to have little efficacy in heart failure, where the preference is intravenous iron products. Most clinical studies have been performed using ferric carboxymaltose with good efficacy in terms of improvements in 6-min walk test distance, pe …
Oral iron products have been shown to have little efficacy in heart failure, where the preference is intravenous iron products. Most clinica …
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.
Macdougall IC, Comin-Colet J, Breymann C, Spahn DR, Koutroubakis IE. Macdougall IC, et al. Adv Ther. 2020 May;37(5):1960-2002. doi: 10.1007/s12325-020-01323-z. Epub 2020 Apr 15. Adv Ther. 2020. PMID: 32297281 Free PMC article. Review.
Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients.
Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M. Takeda Y, et al. Am J Nephrol. 2011;33(5):421-6. doi: 10.1159/000327019. Epub 2011 Apr 19. Am J Nephrol. 2011. PMID: 21502756
The aim of this study was to examine the effect of intravenous saccharated ferric oxide on serum FGF23 levels and mineral metabolism in hemodialysis patients. ...There was also a significant decrease in intact PTH but no changes in serum calcium and phosphoru …
The aim of this study was to examine the effect of intravenous saccharated ferric oxide on serum FGF23 levels and miner …
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Shimizu Y, et al. Bone. 2009 Oct;45(4):814-6. doi: 10.1016/j.bone.2009.06.017. Epub 2009 Jun 23. Bone. 2009. PMID: 19555782
While it has been shown that saccharated ferric oxide induces hypophosphatemic osteomalacia, the mechanism of this hypophosphatemia remains to be clarified. ...All these biochemical features improved by the cessation of saccharated ferric oxi …
While it has been shown that saccharated ferric oxide induces hypophosphatemic osteomalacia, the mechanism of this hypo …
Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.
Dave CV, Brittenham GM, Carson JL, Setoguchi S. Dave CV, et al. Ann Intern Med. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. Epub 2022 Mar 29. Ann Intern Med. 2022. PMID: 35344378
RESULTS: The adjusted IRs for anaphylaxis per 10 000 first administrations were 9.8 cases (95% CI, 6.2 to 15.3 cases) for iron dextran, 4.0 cases (CI, 2.5 to 6.6 cases) for ferumoxytol, 1.5 cases (CI, 0.3 to 6.6 cases) for ferric gluconate, 1.2 cases (CI, 0.6 to 2.5 cases) …
RESULTS: The adjusted IRs for anaphylaxis per 10 000 first administrations were 9.8 cases (95% CI, 6.2 to 15.3 cases) for iron dextran, 4.0 …
681 results